About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNANCT03374826

PET-MRI for Axillary Staging in Node Negative Breast Cancer Patients

Axillary lymph node status is an important prognostic factor for patients with breast cancer. After breast cancer diagnosis, current nodal staging consists of axillary ultrasound (US) combined with ti...

Lead sponsor: Maastricht University Medical Center•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Maastricht University Medical Center

Collaborators

Erasmus Medical Center

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•1. Female patient with histologically confirmed breast cancer and clinically confirmed negative lymph nodes in the axilla, scheduled to undergo SLNB
•2. Patients who are willing and able to undergo the study procedures
•3. The patient has provided personally written informed consent

Exclusion Criteria

•1. Patients treated with neoadjuvant systemic therapy prior to axillary nodal staging
•2. Patients with clinically positive axillary lymph nodes
•3. Age \< 18 years
•4. Inability to provide informed consent
•5. Pregnancy
•6. Weight \>100 kg (because of the format of the PET/MRI scanner)
•7. General contraindications for MRI (such as pacemaker, aneurysm clips, metallic device in their body, severe claustrophobia) or PET (i.e. known allergy to 18F-FDG)
•8. Hyperglycaemia (\> 11 mmol/L) at the time of 18F-FDG injection

Related studies

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

NCT07586215 · Breast Cancer Metastatic

RC48-ADC in HER2-low Advanced Breast Cancer

NCT05831878 · Advanced Breast Cancer

RECRUITINGPhase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

RECRUITINGPhase 2

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998 · Breast Cancer

RECRUITINGPhase 4

A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients

NCT07578064 · Breast Cancer, Bone Marrow Suppression

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 31, 2023Terms

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment125

Start dateFeb 2018

Last updatedOct 31, 2023

Condition

Breast Cancer Breast Neoplasms Breast Diseases

Locations shown

Maastricht University Medical Center

Maastricht

Erasmus Medical Center

Rotterdam

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 31, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions